DK2324111T3 - Yderzone-tumorceller samt fremgangsmåde til fremstilling deraf samt anvendelse deraf - Google Patents

Yderzone-tumorceller samt fremgangsmåde til fremstilling deraf samt anvendelse deraf

Info

Publication number
DK2324111T3
DK2324111T3 DK09778433.4T DK09778433T DK2324111T3 DK 2324111 T3 DK2324111 T3 DK 2324111T3 DK 09778433 T DK09778433 T DK 09778433T DK 2324111 T3 DK2324111 T3 DK 2324111T3
Authority
DK
Denmark
Prior art keywords
preparation
well
tumor cells
outer zone
zone tumor
Prior art date
Application number
DK09778433.4T
Other languages
English (en)
Inventor
Bjorn Scheffler
Matthias Simon
Oliver Bruestle
Martin Glas
Ulrich Johannes Herrlinger
Original Assignee
Life & Brain Gmbh
Univ Bonn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life & Brain Gmbh, Univ Bonn filed Critical Life & Brain Gmbh
Application granted granted Critical
Publication of DK2324111T3 publication Critical patent/DK2324111T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0622Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058Neurological cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK09778433.4T 2008-09-10 2009-09-09 Yderzone-tumorceller samt fremgangsmåde til fremstilling deraf samt anvendelse deraf DK2324111T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19164008P 2008-09-10 2008-09-10
PCT/EP2009/006547 WO2010028820A2 (en) 2008-09-10 2009-09-09 Peripheral zone tumor cells, methods for their preparation and use

Publications (1)

Publication Number Publication Date
DK2324111T3 true DK2324111T3 (da) 2013-09-30

Family

ID=41398932

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09778433.4T DK2324111T3 (da) 2008-09-10 2009-09-09 Yderzone-tumorceller samt fremgangsmåde til fremstilling deraf samt anvendelse deraf

Country Status (5)

Country Link
US (1) US9103819B2 (da)
EP (1) EP2324111B1 (da)
AU (1) AU2009291203B2 (da)
DK (1) DK2324111T3 (da)
WO (1) WO2010028820A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2437159C1 (ru) * 2010-04-26 2011-12-20 Государственное общеобразовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) Способ визуализации астроглиального вала в диагностике низкодифференцированных глиом
ES2537403T3 (es) 2010-07-27 2015-06-08 Genomic Health, Inc. Método para usar la expresión génica para determinar el pronóstico de cáncer de próstata
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images
EP2784510A1 (en) * 2013-03-25 2014-10-01 Universität Zu Köln Methods of diagnosing and differentiating oncocytoma and malignant renal carcinoma as well as products and uses relating thereto
EP4378531A3 (en) 2017-03-09 2024-09-04 Thomas Jefferson University Methods and compositions for treating cancers using antisense

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072345A1 (en) * 1997-06-20 2004-04-15 Altaba Ariel Ruiz I. Method and compositions for inhibiting tumorigenesis
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
CA2447400A1 (en) * 2003-09-12 2005-03-12 The Hospital For Sick Children Brain tumor stem cells
US20070037224A1 (en) * 2005-08-11 2007-02-15 Hamer Peter J Quantitative assays for PDGFR-beta in body fluids
WO2007062138A2 (en) * 2005-11-23 2007-05-31 Applera Corporation Methods and compositions for treating diseases targeting human prominin-1(cd133)
WO2007134274A2 (en) 2006-05-12 2007-11-22 Attenuon, Llc Antibodies to urokinase- type plasminogen activator receptor(upar)bind cancer stem cells: use in diagnosis and therapy
WO2008033393A2 (en) * 2006-09-11 2008-03-20 University Of Florida Isolation, expansion and uses of tumor stem cells
DK2328923T3 (da) * 2008-09-02 2016-03-21 Cedars Sinai Medical Center Cd133-epitoper

Also Published As

Publication number Publication date
EP2324111B1 (en) 2013-07-03
WO2010028820A2 (en) 2010-03-18
WO2010028820A3 (en) 2010-06-17
AU2009291203A1 (en) 2010-03-18
AU2009291203B2 (en) 2015-01-22
EP2324111A2 (en) 2011-05-25
US9103819B2 (en) 2015-08-11
US20110052642A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
DK3130923T3 (da) Terapeutiske fremgangsmåder i forbindelse med cancerstamceller
IL252119B (en) Improved cell composition and methods of making the same
PT2577318T (pt) Método de diferenciação de nocicetor de células estaminais embrionárias humanas e utilizações do mesmo
BRPI0909367A2 (pt) calçado e método de fabricação do mesmo
DK2761126T3 (da) Wellbore stimulation assemblies and methods of using the same
GB201013989D0 (en) Biological materials and methods of using the same
SMT201600050B (it) Mezzi e metodi per trattare il dlbcl
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
PL2358756T3 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
DK2526254T3 (da) Wellbore knock-out chamber and related methods of use
EP2714970A4 (en) Enzyme QUANTIFICATION
PL2657253T3 (pl) Przeciwciała anty-CD79b i immunokoniugaty i sposoby stosowania
PL2552959T3 (pl) Przeciwciała przeciwko MUC16 i metody stosowania
PL2506850T3 (pl) Sposoby podawania terapii pirfenidonem
HRP20160169T1 (xx) Uäśinkovita hidoliza lignoceluloze s integriranom proizvodnjom enzima
EP2367866A4 (en) POLYESTER, MANUFACTURING METHOD THEREFOR AND USE
EP2761016A4 (en) REDOX REAGENT COMPOSITION FOR ELECTROCHEMICAL BIOSENSOR AND BIOSENSOR CONTAINING THE SAME
IL236182A0 (en) Methods for detecting diseases or conditions using circulating diseased cells
SMT201600332B (it) Composizioni e metodi per l’aumento dell’attivitàtelomerasica
EP2242854A4 (en) COMPOUNDS AND USES THEREOF
KR100977015B9 (ko) 콘크리트 부유체 및 이를 이용한 부유조립체
BRPI0917684A2 (pt) método terapêutico homeopático
BR112013011232A2 (pt) batom e outros cosméticos e método de produção
DK2324111T3 (da) Yderzone-tumorceller samt fremgangsmåde til fremstilling deraf samt anvendelse deraf
BRPI1010684A2 (pt) método para determinar o potencial cardiorregenerativo de células mamíferas